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three specific problems associated with the use of RCT
data which may create misleading results: randomization
and sample selection bias, clinically appropriate compar-
ator groups, and indirect treatment effects. These issues
are illustrated with a decision model analyzing Medi-
care's coverage of erythropoietin (EPO) for patients with
End-Stage Renal Disease (ESRD). We show how logistic
and multiple regression can be used to estimate branch
probabilities and payoffs for each treatment group. The
incorporation of additional data from the United States
Renal Data System into the model enables us to update
probabilities and payoffs when patients are not randomly
assigned to treatment modalities. To highlight the poten-
tial bias that exists when models rely solely on RCT data,
we compare our results to a previous study in which the
authors employed a computerized decision model to esti-
mate the net costs to Medicare of EPO coverage at 1 and
5 years. This exercise will offer policy analysts and others
a method of updating RCT-based decision models to
more accurately reflect clinical practice and predict policy
effects.
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COMPARING COMPUTERIZED OPTIONS IN
PHARMACOECONOMICS: SPREADSHEETS,
DECISION TREES, AND EDUCATIONAL
TOOLS: AN OPEN WORKSHOP FOR
DEMONSTRATING SOFTWARE
McGhan WF
Philadelphia College of Pharmacy and Sciences, Philadelphia,
PA, USA
This session is intended for sharing and comparing com-
puter software applications for research, management,
and practice. Software applications will be demonstrated
for decision analysis, cost effectiveness analysis, multi-
attribute utility computation, and assessing patient utili-
ties. Desktop applications will be discussed. Laptop and
handheld computer software will be demonstrated. Phar-
macoeconomic software allows data to be analyzed from
different perspectives: patient, provider, hospital, man-
aged care, and society. Software models also allow assess-
ment of health care products or services from different
quantitative perspectives: cost of illness, cost minimiza-
tion, cost-benefit, cost-effectiveness, and cost-utility. The
integration of decision analysis and spreadsheets will also
be discussed. Software is utilized to collect information,
analyze data, present findings, or educate managers, pro-
viders and patients. Pros and cons of each analytical and
software approach will be discussed. Participants are en-
couraged to bring their own laptops to demonstrate their
own software or related Internet offerings in an informal
roundtable fashion. Software beta versions allowed; "vi-
ruses" discouraged.
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DECISION ANALYSIS: WHAT IS ITS UTILITY FOR
PHARMACOECONOMIC ANALYSIS?
Caro JJ, Migliaccio-Walle K
Caro Research, Boston, MA, USA
Among many techniques available for pharmacoeco-
nomic analysis (PEA), some, such as decision analysis
(DA), have been formally defined, whereas others are still
in the early stages of development and are less well de-
fined. Used for quite some time in the business sector, DA
has been adopted for PEA for its apparent straightfor-
ward nature and ease of use.
METHODS: To evaluate the utility of DA techniques for
PEA, an analysis of treatment for gastroesophageal reflux
disease (GERD) will be presented as an example and the
basic tenets of DA examined.
RESULTS: Although the basic decision tree for the
GERD model appeared straightforward, it became clear
upon implementation just how difficult it is to fit disease
management and progression into such a model. Instead
of the standard two alternative-two outcome textbook
examples, there were six initial choices, three potential
early outcomes, and countless subsequent resulting "next
steps." As with most PEA, it was also necessary to explic-
itly account for time as many model elements depended
on time.
CONCLUSIONS: Among problems with DA are: time is
not explicitly accounted for, the use of dual values (cost,
effectiveness) was not intended, and cost and effective-
ness values must be specified at a terminal node though
they are actually cumulative. Thus, DA is clear only for
simple models - more often it is overly complex, compu-
tationally inefficient, and very difficult to validate. Tech-
niques better suited to PEA will be discussed. Any person
who uses, or is interested in using, PEA in his or her work
will benefit from attending this session.
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ISSUES IN DEVELOPING ECONOMIC MODELS
FOR MANAGED CARE: THE CASE OF
OSTEOPOROSIS PREVENTION
Funk Orsini pi, Mullins CD2, Weiss SR2, Preston KL'
'PAREXEL International, Alexandria, VA, USA; -University of
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Although efficacy and safety data remain the mainstay of
formulary decisions, the need for economic evaluation of
new pharmaceutical products has become increasingly
important within the managed care environment. For
many new products, insufficient information is generated
from clinical trials to conduct a comprehensive economic
evaluation. Therefore, economic modeling is often the
only feasible option for delivering timely information to
decision makers about a new product's value. Unfortu-
nately, economic models presented to managed care plans
often have limited usefulness because they lack relevance
or applicability to the plan's members or the overall goals
